ArticleBriefings in bioinformatics2026
MHCXGraph: a graph-based approach to detecting T-cell receptor cross-reactivity.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The T-cell receptor (TCR) recognition of multiple peptides presented by the major histocompatibility complex (MHC) is a key natural phenomenon, enabling the T-cell repertoire to respond to a broad array of antigens. Despite its importance to the immune response, T-cell cross-reactivity poses a major challenge for the development of novel T cell-based therapies. In this study, we present MHCXGraph, a graph-based computational approach for identifying conserved and immunologically relevant regions across multiple structures of peptides bound to MHC molecules (pMHC). Our approach provides three operational modes: Multiple, Pairwise, and Screening, with user-defined parameters, allowing flexible configuration according to specific scientific needs while delivering fully interpretable results through user-friendly interfaces. We evaluated MHCXGraph across several case studies, including peptides bound to classical MHC Class I, MHC Class II, unbound human leukocyte antigen (HLA) alleles, and pMHCs containing noncanonical amino acids, demonstrating its ability to capture conserved structural determinants beyond sequence similarity. By integrating structural information with efficient graph-based analysis, MHCXGraph addresses key limitations of sequence-based methods while maintaining computational scalability. Collectively, these results indicate that MHCXGraph can be readily integrated into computational pipelines for T-cell cross-reactivity discovery, especially in the context of $\textit{de novo}$ pMHC engager design and T cell-based vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.